Rahlfs Capital LLC Purchases New Shares in Pfizer Inc. (NYSE:PFE)

Rahlfs Capital LLC purchased a new position in shares of Pfizer Inc. (NYSE:PFE - Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 39,953 shares of the biopharmaceutical company's stock, valued at approximately $1,060,000. Pfizer makes up 1.0% of Rahlfs Capital LLC's holdings, making the stock its 28th largest holding.

Other large investors also recently modified their holdings of the company. Norges Bank bought a new stake in Pfizer in the fourth quarter valued at $2,328,986,000. Charles Schwab Investment Management Inc. increased its holdings in Pfizer by 19.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 155,459,101 shares of the biopharmaceutical company's stock worth $4,124,330,000 after purchasing an additional 25,315,159 shares in the last quarter. Raymond James Financial Inc. bought a new position in Pfizer during the 4th quarter valued at $274,694,000. Massachusetts Financial Services Co. MA boosted its holdings in Pfizer by 7.5% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 76,502,238 shares of the biopharmaceutical company's stock worth $2,029,604,000 after purchasing an additional 5,350,381 shares during the last quarter. Finally, Fisher Asset Management LLC grew its holdings in shares of Pfizer by 79.5% in the fourth quarter. Fisher Asset Management LLC now owns 11,148,116 shares of the biopharmaceutical company's stock valued at $295,760,000 after acquiring an additional 4,938,209 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company's stock.

Pfizer Price Performance

Shares of PFE stock traded down $0.64 during trading hours on Wednesday, reaching $21.20. The stock had a trading volume of 41,668,820 shares, compared to its average volume of 39,854,580. The stock's fifty day simple moving average is $25.59 and its 200 day simple moving average is $26.58. The firm has a market capitalization of $120.22 billion, a PE ratio of 15.09, a PEG ratio of 0.64 and a beta of 0.67. Pfizer Inc. has a 12 month low of $20.77 and a 12 month high of $31.54. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping the consensus estimate of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm had revenue of $17.76 billion for the quarter, compared to analysts' expectations of $17.26 billion. During the same quarter in the prior year, the firm posted $0.10 earnings per share. The business's quarterly revenue was up 24.7% on a year-over-year basis. On average, equities research analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Insider Activity

In other news, Director Ronald E. Blaylock acquired 19,457 shares of the firm's stock in a transaction that occurred on Thursday, February 13th. The shares were bought at an average cost of $25.65 per share, with a total value of $499,072.05. Following the acquisition, the director now owns 27,707 shares in the company, valued at approximately $710,684.55. This represents a 235.84 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.06% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on PFE. Hsbc Global Res raised shares of Pfizer to a "strong-buy" rating in a report on Monday, March 10th. Citigroup reiterated a "neutral" rating on shares of Pfizer in a research note on Thursday, March 27th. Guggenheim restated a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. The Goldman Sachs Group reiterated a "neutral" rating and issued a $25.00 price objective (down previously from $32.00) on shares of Pfizer in a research note on Tuesday. Finally, Bank of America reissued a "neutral" rating and issued a $29.00 target price on shares of Pfizer in a research report on Tuesday, December 10th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have assigned a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $31.07.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.